BHB
ARNA

Bank Hapoalim BM’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Bank Hapoalim BM’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,750
Closed -$40K – 223
2017
Q1 		$40K Buy
+2,750
New +$40.7K 0.01% 206

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank Hapoalim BM's ARNA Position: Q2 2017 in Review

Bank Hapoalim BM sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2017, closing a stake of 2,750 shares — an estimated $40K sold.

Bank Hapoalim BM first reported a position in ARNA in Q1 2017 and held it in 1 quarter. The position peaked at $40K in Q1 2017. 102 funds tracked by Wall St. Rank hold ARNA as of Q2 2017.

  • Bank Hapoalim BM reported no remaining Arena Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Bank Hapoalim BM sold 2,750 Arena Pharmaceuticals Inc shares in Q2 2017, an estimated $40K.
  • Bank Hapoalim BM first reported a position in Arena Pharmaceuticals Inc in Q1 2017 and held it in 1 quarter.
  • Bank Hapoalim BM's Arena Pharmaceuticals Inc position peaked at $40K in Q1 2017.
  • 102 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2017.

Based on Bank Hapoalim BM's 13F filing for Q2 2017, filed 11 Aug 2017.